Journal article
Safety of adjuvant atezolizumab after pneumonectomy/bilobectomy in stage II-IIIA non–small cell lung cancer in the randomized phase III IMpower010 trial
The Journal of thoracic and cardiovascular surgery, v 166(3), pp 655-666
01 Sep 2023
PMID: 36841745
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
Adjuvant atezolizumab is a standard of care after chemotherapy in completely resected stage II-IIIA programmed death ligand-1 tumor cell 1% or greater non–small cell lung cancer based on results from the phase III IMpower010 study. We explored the safety and tolerability of adjuvant atezolizumab by surgery type in IMpower010.
Patients had completely resected stage IB-IIIA non–small cell lung cancer (Union Internationale Contre le Cancer/American Joint Committee on Cancer, 7th Ed), received up to four 21-day cycles of cisplatin-based chemotherapy, and were randomized 1:1 to receive atezolizumab 1200 mg every 3 weeks (≤16 cycles or 1 year) or best supportive care. Adverse events and clinical characteristics were investigated by surgery type (pneumonectomy/bilobectomy or lobectomy/sleeve lobectomy) in the randomized stage II-IIIA population who received 1 or more atezolizumab dose or with 1 or more postbaseline assessment (safety evaluable) for best supportive care.
Overall, 871 patients comprised the safety-evaluable randomized stage II-IIIA population. In the atezolizumab arm, 23% (100/433) received pneumonectomy/bilobectomy and 77% (332/433) received lobectomy/sleeve lobectomy. Atezolizumab discontinuation occurred in 32% (n = 32) and 35% (n = 115) of the pneumonectomy/bilobectomy and lobectomy/sleeve lobectomy groups, respectively. Grade 3/4 adverse events were reported in 21% (n = 21) and 23% (n = 76) of patients in the atezolizumab arms in the pneumonectomy/bilobectomy and lobectomy/sleeve lobectomy groups, respectively. In the atezolizumab arms of the surgery groups, 13% (n = 13) and 17% (n = 55) had an adverse event leading to hospitalization. Atezolizumab-related adverse events leading to hospitalization occurred in 5% (n = 5) and 7% (n = 23) of the surgery groups.
These exploratory findings support use of adjuvant atezolizumab after platinum-based chemotherapy in patients with completely resected stage II-IIIA programmed death ligand-1 tumor cell 1% or more non–small cell lung cancer, regardless of surgery type.
[Display omitted]
Metrics
Details
- Title
- Safety of adjuvant atezolizumab after pneumonectomy/bilobectomy in stage II-IIIA non–small cell lung cancer in the randomized phase III IMpower010 trial
- Creators
- Jay M. Lee - University of California, Los AngelesEric Vallières - Cancer Institute (WIA)Beiying Ding - GenentechAnn Johnson - GenentechJan Bhagwakar - GenentechSanam Rashidi - RocheQian (Cindy) Zhu - GenentechBarbara J. Gitlitz - GenentechBenny Weksler - Allegheny General HospitalKimberly Costas - Providence Regional Medical Center EverettNasser Altorki - New York Hospital Queens
- Publication Details
- The Journal of thoracic and cardiovascular surgery, v 166(3), pp 655-666
- Publisher
- Elsevier
- Grant note
- Genentech Inc (https://doi.org/10.13039/100004328) F. Hoffmann-La Roche Ltd (https://doi.org/10.13039/100007013)
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- Surgery
- Web of Science ID
- WOS:001070996600001
- Scopus ID
- 2-s2.0-85149991300
- Other Identifier
- 991021960642704721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Collaboration types
- Industry collaboration
- Domestic collaboration
- International collaboration
- Web of Science research areas
- Cardiac & Cardiovascular Systems
- Respiratory System
- Surgery